# Hikma Pharmaceuticals Plc 12.3% potential upside indicated by Berenberg Bank

- Link: https://www.directorstalkinterviews.com/hikma-pharmaceuticals-plc-12-3-potential-upside-indicated-by-berenberg-bank/4121186048
- Published: 2025-02-10T13:20:24+00:00
- Author: Charlotte Edwards

**[Hikma Pharmaceuticals Plc](https://www.directorstalkinterviews.com/ftse-company/hikma-pharmaceuticals/hik.l)**
with ticker (LON:HIK) now has a potential upside of 12.3% according to Berenberg
Bank.
HIK.LBerenberg Bank set a target price of 2,560 GBX for the company, which
when compared to the Hikma Pharmaceuticals Plc share price of 2,280 GBX at opening
today (10/02/2025) indicates a potential upside of 12.3%. Trading has ranged between
1,750 (52 week low) and 2,302 (52 week high) with an average of 421,618 shares exchanging
hands daily. The market capitalisation at the time of writing is £5,098,949,472.
Hikma Pharmaceuticals PLC is a pharmaceutical company. The principal activities 
of the Company are the development, manufacture and marketing of a range of generic,
branded and in-licensed pharmaceutical products. The Company operates through three
segments: Injectables, Branded and Generics. The Injectables segment supplies hospitals
across its markets with generic injectable products, supported by its manufacturing
facilities in the United States, Europe and Middle East/North Africa (MENA). It 
is also engaged in the finished dosage form (FDF) business and has a manufacturing
facility in Cleveland, Ohio. The Branded segment supplies branded generics and in-
licensed patented products from its local manufacturing facilities to retail and
hospital customers across the MENA region. The Generics segment supplies oral and
other non-injectable generic and specialty products to the United States retail 
market, leveraging its manufacturing facility in Columbus, Ohio.

Share on:
